‘Pricing and Market Access Outlook: 2017 Edition’ includes fresh analysis from QuintilesIMS of market forces and pricing policy based on facts and figures behind approvals of new molecular entities in 2015.
The ability to extract insights from big data is quickly becoming a key factor for competitive advantage in every industry, and Life Sciences is no different.
Pricing and market access (P&MA) are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need